Metastatic-Breast-Cancer

Conference Coverage

Third-Line Chemotherapy With or Without Trastuzumab-Based Therapy for Metastatic Breast Cancer

12/06/2021

The inclusion of trastuzumab-based therapy with chemotherapy was associated with improved survival outcomes compared with chemotherapy alone for the third-line treatment of metastatic breast cancer.

The inclusion of...

12/06/2021

Journal of Clinical Pathways

Conference Coverage

Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases

12/06/2021

Janelle Bradley ;

Palbociclib plus letrozole is associated with improved outcomes compared to letrozole alone for the first-line treatment of patients with HR-positive, HER2-negative metastatic breast cancer with lung or liver metastases.

Palbociclib plus letrozole is...

12/06/2021

Journal of Clinical Pathways

News

Anti-HER2 Therapy Shown to Decrease Expression in Metastatic Breast Cancer

09/29/2021

Findings were shown at the virtual 2021 ESMO Congress to support anti HER2 therapy in early metastatic breast cancer as a method to alter the molecular profile and prognosis of mBC.

Findings were shown at the...

09/29/2021

Oncology

News

National Analysis Provides Greater Insights in HER2-Low Metastatic Breast Cancer

09/29/2021

Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.

Findings from a national...

09/29/2021

Oncology

Dr Gatti-Mays Discusses DESTINY-Breast03 Trial Results

09/29/2021

Margaret Gatti-Mays, MD, MPH, The Ohio State University, discusses the phase 2 DESTINY-Breast03 trial, data for which were presented at the 2021 ESMO Congress.

Margaret Gatti-Mays, MD, MPH,...

09/29/2021

Oncology

Videos

Dr Chumsri Discusses Real-World Outcomes of ICIs for HR+, HER2- Metastatic Breast Cancer

09/28/2021

Saranya Chumsri, MD, Mayo Clinic, FL, highlights outcomes from a real-world study of ICIs to treat HR+, HER2-, metastatic breast cancer with a high tumor mutational burden.

Saranya Chumsri, MD, Mayo...

09/28/2021

Oncology

Clinical Videos

Kevin Punie, MD, Discusses Novel Therapy Significantly Improving QOL Over SOC in 2L+ mTNBC

09/24/2021

Dr Punie, UZ Leuven, Belgium, discusses new data from the Phase 3 ASCENT study of sacituzumab govitecan-hziy in patients with relapsed or refractory metastatic TNBC who received two or more prior systemic therapies, at least one of them for...

Dr Punie, UZ Leuven, Belgium,...

09/24/2021

Oncology